Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | ACHE | P22303 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | CDK4 | P11802 | 3/20 | 0.59 |
| ▸ | CCND1 | P24385 | 3/20 | 0.59 |
| ▸ | BCHE | P06276 | 2/20 | 0.59 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.57 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4628422 | 0.80 | MAPT (0.71) | NPC1RAB9APOLBACHEMAPT | |
| SCHEMBL15151736 | 0.78 | MEN1 (0.64) | NPC1RAB9APOLBACHECDK4 | |
| SCHEMBL4629252 | 0.77 | NPC1 (0.69) | NPC1RAB9AMAPTKDM4EALDH1A1 | |
| SCHEMBL26429907 | 0.77 | SIRT1 (0.73) | NPC1RAB9APOLBACHEMAPT | |
| SCHEMBL10824173 | 0.77 | MTNR1A (0.69) | NPC1RAB9APOLBMAPTKCNA5 | |
| SCHEMBL13645785 | 0.77 | MTNR1A (0.69) | NPC1RAB9ASIRT1MTNR1AKDM4E | |
| SCHEMBL4627416 | 0.77 | NPC1 (0.67) | NPC1RAB9AMAPTKDM4EALDH1A1 | |
| SCHEMBL4628732 | 0.76 | KMT2A (0.66) | NPC1RAB9AMAPTKDM4EALDH1A1 | |
| SCHEMBL4628766 | 0.74 | NPC1 (0.61) | NPC1RAB9APOLBMAPTKDM4E | |
| SCHEMBL6516526 | 0.74 | GPR84 (0.61) | NPC1RAB9APOLBACHEMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1918272-A1 | Pharmaceutically active compounds and methods of use | Wyeth a Corporation of the State of Delaware (US) | 2008-05-07 | — | — | EP | disclosed |
| EP-1032556-B1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | WYETH CORP (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20060270741-A1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | US | disclosed |
| US-7041702-B1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| EP-1032556-A4 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE INC (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-1032556-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 2000-09-06 | — | — | EP | disclosed |
| WO-1999020599-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270741-A1 | Pharmaceutically active compounds and methods of use | GBA1, CTSA, GAA | NPC1 140/4885RAB9A 617/4885POLB 2690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.